Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Health systems/plans share common coverage vision for Clarinex, OTC Claritin

Newsletter